entertainment -WSS

entertainment

author：entertainment 2025-09-28 01:40:11 - browse：31

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

WSS

Grail's uphill battle for Medicare to cover its cancer screening test

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Zyn nicotine pouches become unlikely player in latest culture war

Boston competes with Raleigh

Cuban government calls US nuclear submarine stop a 'provocative escalation'

A Greenpeace activist is fined for crash

Wikipedia

entertainment

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Wegovy leads to weight loss. Can it treat depression, too?

Tori Bowie and the unacceptable rates of Black maternal death

France's anti

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Guidelines to prevent youth baseball injuries need more muscle

New clues to why women have higher risk of autoimmune disorders

Moonlake's readout produced a cash windfall. Risks remain

Antibody drugs appear effective. Now can we make enough of them?

hotspot

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Syphilis numbers in the United States reach record heights

Why you shouldn’t ask, “What country has the best health care?”

Digital health funding stays low as a new reality sets in

France's anti

Vermont grapples with historic flooding as more rainstorms head for Northeast

leisure time

knowledge

hotspot

focus